Executive Overview
In the spring of 2024, Yuchen “Sue” Tu—a conservatory-trained viola player, science fiction enthusiast, and aspiring U.S. Army ROTC cadet from Chongqing, China—found herself scrolling through Instagram when a precision-targeted advertisement caught her eye. The ad offered an enticing proposition: free egg freezing for young, ambitious women. To prequalify, all Sue had to do was complete a two-minute quiz.
At just 24 years old, living in New York City where traditional out-of-pocket egg freezing hovers around $18,000, Sue thought she had stumbled upon an incredible loophole. The company behind the pitch was Cofertility, a venture-backed fertility startup launched in Los Angeles in 2022. Cofertility’s mission, spearheaded by CEO and former Uber employee Lauren Makler, is built on a catchy mantra: "The best time to freeze your eggs is when you can least afford it."
The catch? In the United States, there is no such thing as free health care. Instead of paying with cash, clients pay with a biological currency they already possess: their own eggs. Under Cofertility’s "Split" program, participants agree to donate half of their retrieved eggs to "intended parents" who cannot conceive without assistance, while keeping the remaining half for their own future family planning.
While Cofertility markets this model as a human-centered, empowering alternative to the traditional commercial fertility market, an investigative look reveals a complex, high-stakes ecosystem. Beneath the slick, pastel-colored marketing and the rhetoric of female empowerment lie profound medical risks, questionable financial tradeoffs, and an escalating debate over whether gamete-sharing models commodify human reproduction under the guise of feminist altruism.
Detailed Chronology: Sue Tu’s Investigation Into Cofertility
The Hook and the Honeymoon Phase
Sue easily passed Cofertility’s initial quiz. Shortly after, she was video-chatting with a company representative who gushed about how Sue would be securing her own future while making a family’s dreams come true. Spotting a piano in the background of Sue’s Zoom call, the employee even asked to record her playing, believing it would entice prospective parents looking for the genes of a "piano prodigy"—despite Sue politely correcting them that her instrument was the viola.
Intrigued by the booming fertility care industry and curious about the inner workings of such a startup, Sue signed a contract with Cofertility on July 29, 2025.
Initially, her interactions with her "member advocate"—a company liaison tasked with managing her medical updates—were overwhelmingly warm, albeit peppered with an effusive use of smiley faces that Sue found slightly saccharine. However, the tone shifted drastically after her first egg retrieval on September 17, 2025.
The Medical Toll and Corporate Chills
From her first retrieval, doctors harvested 26 mature eggs, all of which immediately became Cofertility merchandise, earmarked for sale to intended parents. Sue received a token gesture at her door—a "very, very, very cheap flower" with a thank-you note—followed almost immediately by physical symptoms that felt like a hyper-amplified menstrual period: a fog of pain, bleeding, and sluggish exhaustion.
While still recovering, Sue’s member advocate called to schedule her second retrieval—the batch Sue would actually get to keep. Per her contract, Sue had a year to complete the second cycle, and she suggested waiting six months to focus on her health and schooling. According to Sue, this hesitation made her advocate "very upset." The company wanted her to go through a second round by November.
As Sue tried to navigate the platform, she noticed warning pages reading "Oops! Something went wrong" under Cofertility’s signature teal banners whenever she tried to view her donor profile. The warmth of the company had evaporated, replaced by a cold, transactional demeanor now that the upcoming cycle would yield no immediate profit for them.
Going Undercover: The Creation of "Yang"
Suspicious of how she was being marketed, Sue hatched an undercover investigation. To test the platform, she created a fake intended parent account under the name "Yang," searching specifically for East Asian donors.
The day after her second retrieval—which yielded another robust harvest of 27 eggs—Sue logged into Yang’s inbox. An email from a Cofertility employee touted a new donor on the platform: "She’s a professional musician who is also pursuing international relations and multilingual studies while training with ROTC… We believe she’ll match very quickly. I’d recommend placing a hold on her profile."
The full batch of Sue’s eggs was being marketed to intended parents for a staggering $83,700.
Digging deeper, Sue discovered that Cofertility’s website architecture, color schemes, and branding bore a striking resemblance to a California-based site called My Asian Donor, which markets to domestic and overseas clients where egg donation is heavily restricted or illegal.
Alarmed, Sue emailed Cofertility CEO Lauren Makler and COO Brittany Izrailov with her findings on November 21, leading to a tense Zoom meeting where executives questioned her mental health rather than addressing her intellectual property concerns. Shortly after, Cofertility cut ties with Sue, agreeing to terminate her contract, return her second batch of eggs, and issue a second rider nullifying the first.
Before her departure, however, Sue compiled a massive, 75-page dossier documenting what she termed "commercialized eugenics" and data security vulnerabilities surrounding the deep psychological, medical, and intergenerational data collected from thousands of applicants who never complete a cycle. On January 12, 2026, she mailed her dossier to the Inspector General’s office at the U.S. Department of Defense. Four days later, Cofertility discovered Yang’s fake account on Sue’s device and officially terminated her access.
Supporting Context & Metrics: The Economics and Realities of Egg Freezing
The Gen Z "Biohacking Imperative"
Cofertility is part of a broader cultural shift where the age-old pressure to reproduce has been repackaged as a "biohacking imperative with a feminist sheen." Industry surveys show that roughly three in five Gen Z women are concerned about their fertility, despite being years away from any biological cliff.
Venture capital has heavily backed this anxiety. Cofertility itself secured $16 million in funding following a Series A round announced in 2024. Startups across the sector now utilize AI-backed conception-probability calculators, money-back guarantees for frozen eggs that fail to result in live births, and aggressive digital ad campaigns targeting young women on social media.
The Mathematics of "Splitting"
According to prominent reproductive endocrinologists, the mathematics of Cofertility’s "Split" model present hidden hurdles. Northwestern University fertility specialist Dr. Eve Feinberg points out that "the egg donor is not going to be able to have the best likelihood of having a live birth from half a cycle."
Human eggs are fragile single cells. When a patient undergoes hormonal stimulation, dozens of follicles are forced to mature. However, due to natural biological attrition:
- Many eggs will fail to mature fully.
- Others will prove to be genetically abnormal upon attempted fertilization.
- Some will not survive the freezing and thawing process.
By splitting a retrieval batch 50/50, donors cannot guarantee that their best-quality genetic material remains in their own half. Furthermore, because Cofertility requires donors to have high ovarian reserves (retrieving an average of 24 eggs per cycle, leaving 12 retained), the physical toll is immense.
Medical Risks: OHSS and Beyond
The hormonal regimens required for egg retrieval carry documented medical risks, most notably Ovarian Hyperstimulation Syndrome (OHSS). In severe cases, swollen blood vessels leak fluid into the abdomen, requiring hospitalization, fluid draining, or treatment for blood clots that can lead to heart attacks or strokes. While industry literature often cites severe OHSS rates between 0.1% and 2%, cross-sectional studies published in medical journals like Fertility & Sterility suggest that up to 10.5% of donors report OHSS symptoms, and up to a third experience milder forms of the syndrome.
Constrained Choices vs. True Empowerment
Bioethicists argue that programs like Cofertility’s represent what sociologists call a "constrained choice." Dr. Emily Packard Dawson of the University of Pennsylvania notes: "Empowerment implies that you are making a choice with full genuine autonomy, but if you are making a choice to freeze your eggs because day care is so expensive and you have heavy student loan debt and you just need to push off to a different time, is that empowering?"
Official Statements and Institutional Responses
Throughout the reporting of these controversies, Cofertility has vigorously defended its business model and operational integrity:
- On Care and Pressure: A Cofertility spokesperson stated that "the care a donor receives for a cycle has nothing to do with whether the eggs are being donated or kept," and attributed the fast turnaround on subsequent cycles to "familiarity, not pressure."
- On Genetic Material Allocation: The company emphasized that a donor’s eggs go exclusively to the intended parents she is matched with through their program, explicitly denying any practice of reselling eggs.
- On External Connections: Cofertility firmly denied any relationship with or connection to My Asian Donor.
- On Transparency: The company maintains that topics covered during initial intakes have evolved over time and that comprehensive informed consent is standard procedure during medical clearance calls.
Future Outlook
The commercial gamete market sits at a volatile intersection of modern biotechnology, corporate venture capital, and deeply personal human psychology.
For young women facing crushing economic realities, skyrocketing costs of living, and mounting student debt, platforms like Cofertility offer an alluring promise: a way to hedge against biological uncertainty without paying tens of thousands of dollars out of pocket. Yet, as the experiences of donors like Sue Tu and "Mona"—alongside frustrated intended parents like Greg and Alexis—demonstrate, the middleman-driven model introduces layers of bureaucracy, miscommunication, and emotional strain.
As regulatory bodies, bioethicists, and lawmakers begin to cast a more critical eye on the direct-to-consumer fertility sector, the industry will face mounting pressure to bridge the gap between inspiring marketing slogans and transparent medical realities. For now, thousands of young women continue to scroll through pastel-colored web portals, weighing the price of their biological future against the hidden costs of the fertility economy.
